lonza to build new smallmolecule manufacturing plant in

Provide customers with tailor-made solutions

Lonza to build new small-molecule manufacturing plant in ...

Apr 23, 2021  Lonza AG (Basel, Switzerland) announced the construction of a new small molecule manufacturing complex at its Visp, Switzerland site. The new manufacturing complex will occupy an overall footprint of approximately 2,000 m 2 with six levels of manufacturing space. The complex will offer several opportunities for future expansions supporting the small molecules technologies offering,

Get Price

Lonza to build mRNA and small-molecule plants in Visp

Apr 29, 2021  Separately, Lonza plans to spend $212 million on a small-molecule manufacturing complex at the Visp site. The 2,000 m 2 facility will support

Get Price

Lonza to build new small-molecule manufacturing plant in ...

Lonza to build new small-molecule manufacturing plant in Switzerland ... Lonza AG (Basel, Switzerland) announced the construction of a new small molecule manufacturing complex at its Visp, Switzerland site. The new manufacturing complex will occupy an overall footprint of approximately 2,000 m2 with six levels of manufacturing space. The ...

Get Price

Lonza to build new small-molecule manufacturing plant in ...

Lonza AG (Basel, Switzerland) announced the construction of a new small molecule manufacturing complex at its Visp, Switzerland site. The new manufacturing complex will occupy an overall footprint of approximately 2,000 m2 with six levels of manufacturing space. The complex will offer several opportunities for future expansions supporting the small molecules technologies offering, which ...

Get Price

Lonza unveils plan for $218M small-molecule manufacturing ...

Apr 23, 2021  Swiss CDMO Lonza, currently ramping up its COVID-19 vaccine manufacturing capabilities, unveiled plans to construct a small-molecule manufacturing complex in Visp, Switzerland, with the support of ...

Get Price

Lonza invests yet again, this time with a fill-finish line ...

Aug 23, 2021  Just months after opening a new plant in Guangzhou, China, Lonza is expanding its capacity. Monday, the Swiss CDMO revealed that it is adding a new fill-finish line at the biologics manufacturing ...

Get Price

News Lonza

Apr 23, 2021  Basel, Switzerland, 23 April 2021 – Lonza, a CDMO partner to the biopharma industry, today announced the construction of a new small molecule manufacturing complex at its Visp (CH) site. The new manufacturing complex will occupy an overall footprint of approximately 2000 m 2 with six levels of manufacturing space. The complex will offer ...

Get Price

Lonza invests yet again, this time with a fill-finish line ...

Aug 24, 2021  Just months after opening a new plant in Guangzhou, China, Lonza is expanding its capacity. Monday, the Swiss CDMO revealed that it is adding a new fill-finish line at the biologics manufacturing facility, which opened in the second quarter of this year. The addition is expected to be complete next year and will create more than 150 jobs.

Get Price

Lonza invests yet again, this time with a fill-finish line ...

Aug 23, 2021  Simply months after opening a brand-new plant in Guangzhou, China, Lonza is broadening its capability. Monday, the Swiss CDMO exposed that it is including a brand-new fill-finish line at the biologics producing center, which opened in the 2nd quarter of this year. The addition is anticipated to be total next year and will develop more than 150 ...

Get Price

Lonza Building New Swiss Plant, Expands Moderna COVID-19 ...

Lonza Building New Swiss Plant, Expands Moderna COVID-19 Manufacturing Deal. ... Group (Basel, Switzerland) has announced a series of major projects for its Visp facility in Switzerland, including a new $218 million small molecule manufacturing complex and separate plans to double the drug substance production for Moderna's (NASDAQ:MRNA ...

Get Price

Lonza Announces Construction of a New Small Molecule ...

Apr 26, 2021  Basel, Switzerland, 23 April 2021 – Lonza, a CDMO partner to the biopharma industry, today announced the construction of a new small molecule manufacturing complex at its Visp (CH) site. The new manufacturing complex will occupy an overall footprint of approximately 2000 m2 with six levels of manufacturing space.

Get Price

Lonza invests yet again, this time with a fill-finish line ...

Aug 23, 2021  Just months after opening a new plant in Guangzhou, China, Lonza is expanding its capacity. Monday, the Swiss CDMO revealed that it is adding a new fill-finish line at the biologics manufacturing facility, which opened in the second quarter of this year. The addition is expected to be complete next year and will create more than 150 jobs.

Get Price

Lonza invests yet again, this time with a fill-finish line ...

Aug 23, 2021  Simply months after opening a brand-new plant in Guangzhou, China, Lonza is broadening its capability. Monday, the Swiss CDMO exposed that it is including a brand-new fill-finish line at the biologics producing center, which opened in the 2nd quarter of this year. The addition is anticipated to be total next year and will develop more than 150 ...

Get Price

Lonza invests yet again, this time with a fill-finish line ...

Aug 23, 2021  Just months after opening a new plant in Guangzhou, China, Lonza is expanding its capacity. On Monday, the Swiss CDMO revealed that it is adding a new fill-finish line at the biologics manufacturing facility, which opened in the second quarter of this year. The addition is expected to be complete next year and will create more than 150 jobs.

Get Price

Lonza Building New Swiss Plant, Expands Moderna COVID-19 ...

Lonza Building New Swiss Plant, Expands Moderna COVID-19 Manufacturing Deal. ... Group (Basel, Switzerland) has announced a series of major projects for its Visp facility in Switzerland, including a new $218 million small molecule manufacturing complex and separate plans to double the drug substance production for Moderna's (NASDAQ:MRNA ...

Get Price

Lonza to Expand API Manufacturing Facility ...

Jun 29, 2021  Integrated healthcare solutions supplier Lonza revealed plans Monday to invest CHF 20 million, or about $21.7 million, to expand the API development and manufacturing capabilities at its production site in Nansha, China.. The new mid-scale manufacturing assets at the Nansha site will support the transition of products under development to large-scale production.

Get Price

History Lonza

Lonza announced the construction of two new customer-dedicated conjugation suites for the commercialization of ADC in Ibex ® Dedicate, Visp (CH). 2021. Lonza was recognized by Ethisphere ® as one of the world's most ethical companies in 2021. Lonza announced the construction of a new small molecule manufacturing complex at its Visp (CH) site.

Get Price

News_Details - PHEXCOM

The expansion in China comes during a dizzying year of investment for Lonza, which is going all-in on mammalian cell culture manufacturing. In May, the company revealed that it is spending $935 million to build mammalian facilities at sites in Portsmouth, New Hampshire, and Basel, Switzerland, which would add a combined 550 jobs.

Get Price

Lonza in two expansion deals Speciality Chemicals Magazine

May 03, 2021  Shortly before this, Lonza announced that it was to build a new, CHF 200 million small molecule complex at Visp, focusing on high potency treatments for cancer. This will cover about 2,000 m 2, with six levels of manufacturing space. On completion, it will employ about 200 people.

Get Price

Lonza Inaugurates New Plant for ADC Payload Manufacturing

Nov 06, 2020  Basel/Switzerland – Lonza has recently inaugurated the first of two manufacturing suites for antibody-drug conjugate (ADC) drug-linker (payload) manufacturing at the Visp (CH) site. This first manufacturing suite handles compounds with occupational exposure levels down to 1ng/m3 and is dedicated to the manufacturing platform for ADC drug linkers.

Get Price

Coronavirus: Moderna to build mRNA production plant in ...

Aug 10, 2021  Canada has also promised $126 million for a new National Research Council to build a biologics production plant in Montreal, that is set to make the Novavax vaccine, once it is approved.

Get Price

Lonza to expand manufacturing center in Nansha, China ...

Jun 28, 2021  Lonza AG (Basel, Switzerland) announced new investments in GMP laboratories and mid-scale manufacturing assets at its API manufacturing center in Nansha, China. The investments, totaling over CHF 20 million (around $22 million), will allow Lonza to provide a smoother transition from small-scale to large-scale manufacturing for customers while maintaining Lonza’s global quality and

Get Price

Lonza to build plant for Sanofi - CEN

Mar 03, 2017  Lonza to build plant for Sanofi. A purification vessel at Lonza’s Portsmouth facility. Lonza and Sanofi have signed a supply agreement under which the Swiss chemical maker will operate a

Get Price

The future of highly potent API manufacturing

• Lonza will invest >100MCHF in small molecule manufacturing in its Visp, Switzerland site over the period 2017-2020 • Key themes are highly potent molecules and manufacturing 4.0 • To date 4 major projects forming a continuum of investment: •Monoplant for production of

Get Price

Lonza invests yet again, this time with a fill-finish line ...

Aug 23, 2021  Simply months after opening a brand-new plant in Guangzhou, China, Lonza is broadening its capability. Monday, the Swiss CDMO exposed that it is including a brand-new fill-finish line at the biologics producing center, which opened in the 2nd quarter of this year. The addition is anticipated to be total next year and will develop more than 150 ...

Get Price

Lonza invests yet again, this time with a fill-finish line ...

Aug 23, 2021  Just months after opening a new plant in Guangzhou, China, Lonza is expanding its capacity. Monday, the Swiss CDMO revealed that it is adding a new fill-finish line at the biologics manufacturing facility, which opened in the second quarter of this year. The addition is expected to be complete next year and will create more than 150 jobs.

Get Price

Lonza Updates Plan for New Mammalian Biomanufacturing ...

Apr 07, 2020  Lonza is proceeding with plans for a new mammalian biologics development and manufacturing facility in Guangzhou, China. David Maier, Head of China Strategic Growth Projects, Mammalian Microbial Development Manufacturing, Lonza, outlined the details of the expansion and how it fits into the company’s overall biomanufacturing network at the DCAT Member Company

Get Price

Lonza to expand manufacturing center in Nansha, China ...

Jun 28, 2021  Lonza AG (Basel, Switzerland) announced new investments in GMP laboratories and mid-scale manufacturing assets at its API manufacturing center in Nansha, China. The investments, totaling over CHF 20 million (around $22 million), will allow Lonza to provide a smoother transition from small-scale to large-scale manufacturing for customers while maintaining Lonza’s global quality and

Get Price

Lonza to Expand API Manufacturing Facility ...

Jun 29, 2021  Integrated healthcare solutions supplier Lonza revealed plans Monday to invest CHF 20 million, or about $21.7 million, to expand the API development and manufacturing capabilities at its production site in Nansha, China.. The new mid-scale manufacturing assets at the Nansha site will support the transition of products under development to large-scale production.

Get Price

News Lonza

Dec 15, 2020  Basel, Switzerland and Victoria, Canada, 15 December 2020 – Aurinia Pharmaceuticals Inc. and Lonza today announced they have expanded their exclusive manufacturing relationship. The parties entered into a collaborative agreement to build a dedicated manufacturing capacity within Lonza's existing small molecule API facility in Visp (CH).

Get Price

News_Details - PHEXCOM

The expansion in China comes during a dizzying year of investment for Lonza, which is going all-in on mammalian cell culture manufacturing. In May, the company revealed that it is spending $935 million to build mammalian facilities at sites in Portsmouth, New Hampshire, and Basel, Switzerland, which would add a combined 550 jobs.

Get Price

Lonza in two expansion deals Speciality Chemicals Magazine

May 03, 2021  Shortly before this, Lonza announced that it was to build a new, CHF 200 million small molecule complex at Visp, focusing on high potency treatments for cancer. This will cover about 2,000 m 2, with six levels of manufacturing space. On completion, it will employ about 200 people.

Get Price

Chemical Custom Manufacturing - Lonza

Lonza has extensive experience in chemical custom synthesis, and we offer customers the benefit of a professional RD staff, high quality work, and an excellent customer service. Basic intermediates for the Agrochemical and other industries are produced in continuous, world-class production plants in the heart of Europe to guarantee quality and ...

Get Price

Lonza to build plant for Sanofi - CEN

Mar 03, 2017  Lonza to build plant for Sanofi. A purification vessel at Lonza’s Portsmouth facility. Lonza and Sanofi have signed a supply agreement under which the Swiss chemical maker will operate a

Get Price

Lonza Wraps Up Sale of Specialty Ingredients Business ...

Jul 07, 2021  Pharmaceutical and nutrition products firm Lonza announced that the sale of its Specialty Ingredients business to Bain Capital has closed, the company said in a July 2 release. The transaction was valued at CHF 4.2 billion, or about $4.6 billion. “Since announcing our intention to divest the Specialty Ingredients business, we have made significant progress in consolidating our new structure ...

Get Price

Lonza Ltd. Overview

Lonza to Build New Small Molecule Manufacturing Complex in Visp. Lonza has plans to invest 219 million dollars to construct a new manufacturing complex in Visp, Switzerland. The 2,000 sq m project will comprise a customer dedicated manufacturing line for antibody-drug conjugate payload molecules and will also prove useful for accommodating ...

Get Price

Moderna to sign agreement to build mRNA production plant ...

Aug 10, 2021  Scaling up production to meet huge demand has been at times problematic for the young company. Thus far Moderna has partnered only with Swiss-based Lonza to make the drug substance of the vaccine at facilities in Switzerland and New Hampshire. The vaccine is finished and filled into vials by a number of companies in Europe and the United States.

Get Price

API Synthesis and Manufacturing, Small Molecule

Aug 19, 2021  Lonza to Add New Small-Molecule Manufacturing Complex to Switzerland Site April 26, 2021 Lonza’s new complex will occupy 2000 m2 of the facility with six levels of manufacturing space and will provide room for future small-molecule technologies expansion.

Get Price